Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
8/2/2025
-
Ticker Report
8/1/2025
-
MarketBeat
Enliven Therapeutics (ELVN, $20.07) price may climb as it broke lower Bollinger Band on Jul 29, 2025
7/30/2025
-
Tickeron - Stocks
7/30/2025
-
Tickeron - Stocks
7/26/2025
-
Tickeron - Stocks
7/25/2025
-
Tickeron - Stocks
7/25/2025
-
MarketBeat
7/24/2025
-
MarketBeat
7/24/2025
-
GuruFocus
7/23/2025
-
Tickeron - Stocks
7/22/2025
-
MarketBeat
7/22/2025
-
MarketBeat
7/19/2025
-
MarketBeat
7/18/2025
-
Zacks Investment Research
7/18/2025
-
Ticker Report
7/17/2025
-
TipRanks Financial Blog
7/15/2025
-
MarketBeat
7/15/2025
-
MarketBeat
7/14/2025
-
MarketBeat
7/12/2025
-
Ticker Report
7/11/2025
-
MarketBeat
7/11/2025
-
Tickeron - Stocks
Enliven Therapeutics (ELVN, $22.78) price may drop as it broke higher Bollinger Band on Jul 10, 2025
7/11/2025
-
Tickeron - Stocks
7/10/2025
-
Market News Video
7/10/2025
-
Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
720 647 8519
Address
6200 Lookout Road
Boulder, CO 80301
Boulder, CO 80301
Country
Year Founded
--
Business Description
Sector
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead...
more